Cytokinetics to Announce Second Quarter Results on July 26, 2018
July 12 2018 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is
scheduled to report second quarter results on July 26, 2018 at 4:00
PM Eastern Time. Following the announcement, Cytokinetics’ senior
management will host a conference call at 4:30 PM Eastern Time to
discuss operational and financial results and the company’s outlook
for the future.
The conference call will be simultaneously
webcast and can be accessed from the homepage and in the Investors
& Media section of Cytokinetics’ website at
www.cytokinetics.com. The live audio of the conference call can
also be accessed by telephone by dialing either (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 9599438.
An archived replay of the webcast will be
available via Cytokinetics’ website until August 2, 2018. The
replay will also be available via telephone by dialing (855)
859-2056 (United States and Canada) or (404) 537-3406
(international) and typing in the passcode 9599438 from July 26,
2018 at 7:30 PM Eastern Time until August 2, 2018.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics is collaborating
with Amgen Inc. (“Amgen”) to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other
countries. Cytokinetics is collaborating
with Astellas Pharma Inc. (“Astellas”) to
develop reldesemtiv, a next-generation
FSTA. Reldesemtiv has been granted orphan drug
designation by the FDA for the potential treatment of
spinal muscular atrophy. Reldesemtiv was the subject of a
positive Phase 2 clinical study in patients with spinal muscular
atrophy which showed increases in measures of endurance and stamina
consistent with the mechanism of action. Reldesemtiv is currently
the subject of two ongoing Phase 2 clinical trials in patients with
chronic obstructive pulmonary disease and amyotrophic lateral
sclerosis. Astellas is also conducting a Phase 1b clinical trial
of reldesemtiv in elderly adults with limited mobility.
Astellas holds an exclusive worldwide license to develop and
commercialize reldesemtiv. Licenses held
by Amgen and Astellas are subject
to Cytokinetics' specified co-development and
co-commercialization rights. Cytokinetics continues its
20-year history of innovation with three new muscle biology
directed compounds advancing from research to development in 2018.
For additional information about Cytokinetics,
visit www.cytokinetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:CytokineticsDiane WeiserVice President, Corporate
Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024